Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2436584
Max Phase: Preclinical
Molecular Formula: C23H30F3N3O3
Molecular Weight: 453.51
Molecule Type: Small molecule
Associated Items:
ID: ALA2436584
Max Phase: Preclinical
Molecular Formula: C23H30F3N3O3
Molecular Weight: 453.51
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(Nc1ccc(OC(F)(F)F)cc1)N1CCC2(CCN(C(=O)C3CCCCC3)CC2)C1
Standard InChI: InChI=1S/C23H30F3N3O3/c24-23(25,26)32-19-8-6-18(7-9-19)27-21(31)29-15-12-22(16-29)10-13-28(14-11-22)20(30)17-4-2-1-3-5-17/h6-9,17H,1-5,10-16H2,(H,27,31)
Standard InChI Key: KYPNCYURWUZPAV-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 453.51 | Molecular Weight (Monoisotopic): 453.2239 | AlogP: 5.01 | #Rotatable Bonds: 3 |
Polar Surface Area: 61.88 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.75 | CX Basic pKa: | CX LogP: 4.49 | CX LogD: 4.49 |
Aromatic Rings: 1 | Heavy Atoms: 32 | QED Weighted: 0.70 | Np Likeness Score: -1.32 |
1. Kato Y, Fuchi N, Saburi H, Nishimura Y, Watanabe A, Yagi M, Nakadera Y, Higashi E, Yamada M, Aoki T.. (2013) Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension., 23 (21): [PMID:24035338] [10.1016/j.bmcl.2013.08.054] |
Source(1):